Endogenous Interleukin 6 Is a Resistance Factor for cis-Diamminedichloroplatinum and Etoposide-mediated Cytotoxicity of Human Prostate Carcinoma Cell Lines

Cancer Research

Volumn 55, Issue 20, 1995, Pages 4633-4639

  Borsellino, Nicolo ^a   Bonavida, Benjamin ^a   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PROTEIN P53; SURAMIN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CELL DEATH; CYTOTOXICITY; DNA DAMAGE; DNA SYNTHESIS; DOWN REGULATION; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; R FACTOR; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CARCINOMA; CELL DIVISION; CISPLATIN; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; IMMUNOLOGIC TECHNIQUES; IN VITRO; INTERLEUKIN-6; MALE; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028880675     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics 1995. CA Cancer J. Clin., 45: 8–30, 1995.
2. Huggins, C., and Hodges, C. V. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293–297, 1941.
3. Mahler, C., and Denis L. Management of relapsing disease in prostate cancer. Cancer (Phila.), 70: 329–334, 1992.
4. Yagoda, A., and Petrylak, D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (Phila.), 71: 1098–1109, 1993.
5. Voogd, T. E., Vansterkenburg, E. L. M., Wilting, J., and Janssen, L. H. M. Recent research on the biological activity of suramin. Pharmacol. Rev., 45: 177–203, 1993.
6. Eisenberger, M. A., and Reyno, L. M. Suramin. Cancer Treat. Rev., 20: 259–273, 1994.
7. Akira, S., Taga, T., and Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol., 54: 1–78, 1993.
8. Kawano, M., Hirano, T., Matsuda, T., Taga, H., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, I., Kuramoto A., and Kishimoto, T. Autocrine generation and requirement of BSF/IL-6 for human multiple myelomas. Nature (Lond.), 332: 83–85, 1988.
9. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett., 250: 607–610, 1989.
10. Eustace, D., Han, X., Gooding, R., Rowbottom, A., Riches, P., and Heyderman, E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol. Oncol., 50: 15–19, 1993.
11. Miles, S. A., Rezai, A. R., Salazar-Gonzales, J. F., Meyden, M. V., Stevens, R. H., Logan, D. M., Mitsuyasu, T. T., Taga T., Hirano, T., Kishimoto, T., and Martinez-Maza, O. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin-6. Proc. Natl. Acad. Sci. USA, 87: 4068–4072, 1990.
12. Shimizu, S., Hirano, T., Yoshioka, R., Sugai, S., Matsuda, T., Taga, T., Kishimoto, T., and Konda, S. Interleukin-6 (B-cell stimulatory factor-2)-dependent growth of a Lennert's lymphoma-derived T-cell lines. Blood, 72: 1826–1828, 1988.
13. Yee, C., Biondi, A., Wang, X. H., Iscove, N. N., de Sousa, J., Aarden, L. A., Wong, G. G., Clark, S. C., Messner, H. A., and Minden, M. D. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood, 74: 798–804, 1989.
14. Siegall, C. B., Schwab, G., Nordan, R. P., Fitzgerald, D. J., and Pastan, I. Expression of the interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res., 50: 7786–7788, 1990.
15. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121–139, 1992.
16. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor), 2: 275–280, 1990.
17. Okamoto-Kubo, S., Nishio, K., Heike, Y., Yoshida, M., Ohmori, T., and Saijo, N. Apoptosis induced by etoposide in small-cell lung cancer cell lines. Cancer Chemother. Pharmacol., 33: 385–390, 1994.
18. Skladanowski, A., and Konopa, J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells. Biochem. Pharmacol., 46: 376–382, 1993.
19. Sachs, L., and Lotem, J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood, 82: 15–21, 1993.
20. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, A. M. Wild-type p53 induced apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.) 352: 345–347, 1991.
21. Chomczynski, P., and Sacchi, N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156–159, 1987.
22. Berenbaum, M. C. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res., 35: 269–290, 1981.
23. Lotz, M. Interleukin-6. Cancer Invest., 11: 732–742, 1993.
24. Revel, M. Growth regulatory functions of IL-6 and antitumor effects. Res. Immunol., 143: 769–773, 1992.
25. Chen, L., Mory, Y., Zilberstain, A., and Revel, M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon 02. Proc. Natl. Acad. Sci. USA, 85: 8037–8041, 1988.
26. Takizawa, M., Ohtosh, T., Ohta, K., Yamashita, N., Hiromata, S., Hirai, K., Hiramatsu, K., and Ito, K. Growth inhibition of human lung cancer cell lines by interleukin-6 m vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res., 53: 4175–4181, 1993.
27. Lotem, J., and Sachs, L. Selective regulation of the activity of different hematopoietic regulatory protein by transforming growth factor 01 in normal and leukemic myeloid cells. Blood, 76: 1315–1322, 1990.
28. Lotem, J., Cragoe, E. J., Jr., and Sachs, L. Rescue from programmed cell death in leukemia and normal myeloid cells. Blood, 78: 953–960, 1991.
29. Kawano, M. M., Mihara, K., Huang, N., Tsujimoto, T., and Kuramoto, A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood, 85: 487–494, 1995.
30. Lotem, J., and Sachs, L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor 01 and cancer chemotherapeutic compounds in myeloid leukemic cells. Blood, 80: 1750–1757, 1992.
31. Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., and Epstein, J. Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood, 84: 3063–3070, 1994.
32. Siegsmund, M. J., Yamazaki, H., and Pastan, I. Interleukin-6 receptor mRNA in prostate carincinomas and benign prostate hyperplasia. J. Urol., 151: 1396–1399, 1994.
33. Steiner, M. S. Role of peptide growth factors in the prostate: a review. Urology, 42: 99–110, 1993.
34. Ware, J. L. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev., 12: 287-301, 1993.
35. Liu, X. H., Wiley, H. S., and Meikle, A. W. Androgens regulate proliferation of human prostate cancer cell in culture by increasing transforming growth factor-a (TGF-a) and epidermal growth factor (EGF)/TGF-a receptor. J. Clin. Endocrinol. Metab., 77: 1472–1478, 1993.
36. Story, M. T. Polypeptide modulators of prostatic growth and development. Cancer Surv. 11: 123–146, 1991.
37. Hsieh, W.-S., and Simons, J. Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology. Cancer Treat. Rev., 19: 229–260, 1993.
38. Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J., and Lee, C. H. Autonomous growth of androgen independent human prostatic carcinoma cells. Role of transforming growth factor-a. Cancer Res., 51: 2780–2785, 1991.
39. MacDonald, A., and Habib, F. K. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br. J. Cancer, 65: 177–182, 1992.
40. Dole, M., Nunez, G., Merchant, A. K., Maybaum, J., Rode, K. C., Bloch, C. A., and Castle, V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res., 54: 3253–3259, 1994.
41. Kamesaki, S., Kamesaki, H., Jorgensen, T. J., Tanizawa, A., Pommier, Y., and Cossman, J. Bcl-2 proteins inhibits etoposide-induced apoptosis through its effects on events subsequent to toposiomerase II-induced DNA strands breaks and their repair. Cancer Res., 53: 4251–4256, 1993.
42. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapcutic-induced apoptosis in a human leukemia cell line. Blood, 81: 151–157, 1993.
43. Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M., and Korsmeyer, S. Bcl-2 protein is topographically restricted in tissue characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA, 88: 6961–6965, 1991.
44. English, H. F., Kyprianoun, N., and Isaacs, J. T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate, 15: 233–250, 1989.
45. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940–6944, 1992.
46. Bullock, G., Tang, C., Tourkina, E., Ibrado, A. M., Lutzky, J., Huang, Y., Mahoney, M. E., and Bhalla, K. Effect of combined treatment with interIeukin-3 and interleukin-6 on 4-hydroperoxycyclo-phosphamide-induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp. Hematol., 21: 1640–1647, 1993.
47. Lotem, J., and Sachs, L. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways. Cell Growth & Differ., 5: 321–327, 1994.
48. Nunez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., and Korsmeyer, S. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoietic cell lines. J. Immunol., 144: 3602–3610, 1990.
49. Niesvizky, R., Siegel, D., and Michaeli, J. Biology and treatment of multiple myeloma. Blood Rev., 7: 24–33, 1993.
50. Schwarze, M. M., and Hawley, R. G. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6-mediated upregulation of bcl-xL. Cancer Res., 55: 2262–2265, 1995.
51. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y., and Yoshida, O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6 receptor monoclonal antibody. Cancer Res., 55: 590–596, 1995.
52. Osheroff, N. Biochemical basis for the interaction of type I and type II topoisomerases with DNA. Pharmacol. Ther., 41: 223–224, 1989.
53. Loike, J. D., and Horwitz, S. B. Effect of VP-16 on the intracellular degradation of DNA in Hela cells. Biochemistry, 15: 5443–5448, 1976.
54. Sihna, B., and Trush, M. Free radical metabolism of VP-16 and inhibition of anthracyclin induced lipid peroxidation. Biochem. Pharmacol., 32: 3495–3498, 1983.
55. Usui, N., and Sihna, B. K. Tyrosinase-induced free radical formation from VP-16: relationship to cytotoxicity. Free Radical Res. Comm., 10: 287–293, 1991.
56. Stoyanovsky, D., Yalowich, J., Gantchev, T., and Kagan, V. Tyrosinase-induced phenoxyl radicals of etopsoide (VP-16), interaction with reductans in model systems K562 leukemic cells and nuclear homogenates. Free Radical Res. Comm., 19: 371–386, 1993.
57. Mizutani, Y., and Bonavida, B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-α Cancer (Phila.), 72: 809–818, 1993.
58. Tishler, R. B., Calderwood, S. K., Coleman, N., and Brendan, D. P. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res., 53: 2212–2216, 1993.
59. Santhanam, U., Ray, A., and Sehgal, P. B. Depression of the interleukin-6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA, 88: 7605–7609, 1991.